Clinical Status Overview

  • Primary Cardiac: Coronary Artery Disease, DES x4
  • Other Conditions: Hypertension, Hyperlipidemia, Type 2 Diabetes (No Insulin)
  • Allergies: Neomycin & Mycins antibiotics
    (Reaction unknown / not documented)
 

Care Team & Logistics

  • Cardiac Rehab: Chong Hua Hospital Mandaue, Cebu, Philippines
  • Cardiologist: Dr. Ivie Joyce Parcon
  • Primary Contact: Jacob Range (Son)
    +1 734 377 7099

PCI / Stent Deployment Records

Procedure Date: April 15, 2026 @ UPMC Presbyterian, Pittsburgh, PA  |  Access Site: Right radial artery (No complications)
Anatomical Territory Stent Specifications
OM1/LCx Territory 2 overlapping Biotronik Orsiro Mission drug-eluting stents (2.25 × 15 mm and 3.5 × 40 mm)
LAD Territory 2 overlapping Abbott Xience Skypoint drug-eluting stents (3.0 × 15 mm and 3.5 × 33 mm)
Residual Coronary Disease: Distal LCx/terminal OM3 (~70%); RCA diffuse 30-40% with focal 90% mid-PDA lesion managed medically at time of PCI.

Current Important Medications

Medication Dosage / Schedule Instructions
Aspirin 81 mg once daily
Clopidogrel / Plavix 75 mg once daily
Rosuvastatin 20 mg nightly
Amlodipine-valsartan 5 / 160 mg once daily
Nitroglycerin 0.4 mg SL as needed for chest pain: 1 tablet every 5 minutes, max 3 doses in 15 minutes. Seek emergency care if pain persists.
Antiplatelet / Genetics Note: CYP2C19 genotype is a *1/*2 intermediate metabolizer. This may reduce clopidogrel activation/effectiveness. If ACS, stent thrombosis concern, or antiplatelet change is being considered, cardiology should review whether ticagrelor or prasugrel is appropriate.

Complete Emergency Contacts

Contact Person & Location Phone Number
Mel Compra — Cebu +63 932 273 2653
Jacob Range — USA (Son) +1 734 377 7099
Alexa Range — USA +1 734 673 2304
Jessie Leal — Taguig, Manila +63 917 300 2261
Daisy Monterillo — Pagadian +63 916 644 0160
Angel de Belen — Or. Mindoro +63 916 512 8408